BACKGROUND: In areas of unstable malaria transmission, plasma Plasmodium falciparum histidine-rich protein 2 (PfHRP-2) concentrations parallel total parasite biomass and thus infection severity. However, where transmission is more intense, plasma PfHRP-2 might not reliably predict complications and mortality. METHODS: As part of a prospective case-control study of severe pediatric illness in Madang, Papua New Guinea, we recruited 220 children aged 6 months to 10 years with severe falciparum malaria, 48 with uncomplicated malaria, and 139 healthy controls. Groups were matched by age, sex, and province of parental birth. Plasma PfHRP-2 levels were quantified by validated immunoassay. RESULTS: Detectable plasma PfHRP-2 concentrations were present in 21 healthy controls (15.1%). Although plasma PfHRP-2 levels were higher in the children with clinical malaria (P < .001), there was no difference between those with uncomplicated and severe infections (median, 584 and 456 ng/mL, respectively [interquartile range, 77-1114 and 113-1113 ng/mL, respectively]; P = .43). Log parasitemia, hemoglobin, log plasma bilirubin, and plasma creatinine levels were independently associated with plasma PfHRP-2 levels in multiple regression analysis (P ≤ .014), but coma, blood lactate level, and plasma bicarbonate level were not. The 1 severely ill child who died had a plasma PfHRP-2 concentration of 483 ng/mL, close to the group median. CONCLUSIONS: The clinical and prognostic utility of plasma PfHRP-2 concentrations depends on the epidemiologic circumstances. In areas of intense malaria transmission, plasma PfHRP-2 reflects recent as well as present infections.
BACKGROUND: In areas of unstable malaria transmission, plasma Plasmodium falciparum histidine-rich protein 2 (PfHRP-2) concentrations parallel total parasite biomass and thus infection severity. However, where transmission is more intense, plasma PfHRP-2 might not reliably predict complications and mortality. METHODS: As part of a prospective case-control study of severe pediatric illness in Madang, Papua New Guinea, we recruited 220 children aged 6 months to 10 years with severe falciparum malaria, 48 with uncomplicated malaria, and 139 healthy controls. Groups were matched by age, sex, and province of parental birth. Plasma PfHRP-2 levels were quantified by validated immunoassay. RESULTS: Detectable plasma PfHRP-2 concentrations were present in 21 healthy controls (15.1%). Although plasma PfHRP-2 levels were higher in the children with clinical malaria (P < .001), there was no difference between those with uncomplicated and severe infections (median, 584 and 456 ng/mL, respectively [interquartile range, 77-1114 and 113-1113 ng/mL, respectively]; P = .43). Log parasitemia, hemoglobin, log plasma bilirubin, and plasma creatinine levels were independently associated with plasma PfHRP-2 levels in multiple regression analysis (P ≤ .014), but coma, blood lactate level, and plasma bicarbonate level were not. The 1 severely ill child who died had a plasma PfHRP-2 concentration of 483 ng/mL, close to the group median. CONCLUSIONS: The clinical and prognostic utility of plasma PfHRP-2 concentrations depends on the epidemiologic circumstances. In areas of intense malaria transmission, plasma PfHRP-2 reflects recent as well as present infections.
Authors: Matthew Ndonwi; Oname O Burlingame; Aaron S Miller; Douglas M Tollefsen; George J Broze; Daniel E Goldberg Journal: Blood Date: 2011-04-21 Impact factor: 22.113
Authors: Rajeev K Mehlotra; Rosalind E Howes; Estee Y Cramer; Riley E Tedrow; Tovonahary A Rakotomanga; Stéphanie Ramboarina; Arsène C Ratsimbasoa; Peter A Zimmerman Journal: Am J Trop Med Hyg Date: 2019-05 Impact factor: 2.345
Authors: Thiranut Ramutton; Ilse C E Hendriksen; Juliet Mwanga-Amumpaire; George Mtove; Rasaq Olaosebikan; Antoinette K Tshefu; Marie A Onyamboko; Corine Karema; Kathryn Maitland; Ermelinda Gomes; Samwel Gesase; Hugh Reyburn; Kamolrat Silamut; Kesinee Chotivanich; Kamoltip Promnares; Caterina I Fanello; Lorenz von Seidlein; Nicholas P J Day; Nicholas J White; Arjen M Dondorp; Mallika Imwong; Charles J Woodrow Journal: Malar J Date: 2012-08-16 Impact factor: 2.979
Authors: Ilse C E Hendriksen; Juliet Mwanga-Amumpaire; Lorenz von Seidlein; George Mtove; Lisa J White; Rasaq Olaosebikan; Sue J Lee; Antoinette K Tshefu; Charles Woodrow; Ben Amos; Corine Karema; Somporn Saiwaew; Kathryn Maitland; Ermelinda Gomes; Wirichada Pan-Ngum; Samwel Gesase; Kamolrat Silamut; Hugh Reyburn; Sarah Joseph; Kesinee Chotivanich; Caterina I Fanello; Nicholas P J Day; Nicholas J White; Arjen M Dondorp Journal: PLoS Med Date: 2012-08-21 Impact factor: 11.069
Authors: Ilse C E Hendriksen; Lisa J White; Jacobien Veenemans; George Mtove; Charles Woodrow; Ben Amos; Somporn Saiwaew; Samwel Gesase; Behzad Nadjm; Kamolrat Silamut; Sarah Joseph; Kesinee Chotivanich; Nicholas P J Day; Lorenz von Seidlein; Hans Verhoef; Hugh Reyburn; Nicholas J White; Arjen M Dondorp Journal: J Infect Dis Date: 2012-11-07 Impact factor: 5.226
Authors: Matthew P Rubach; Jackson Mukemba; Salvatore Florence; Bernard John; Benjamin Crookston; Bert K Lopansri; Tsin W Yeo; Kim A Piera; Stephen C Alder; J Brice Weinberg; Nicholas M Anstey; Donald L Granger; Esther D Mwaikambo Journal: PLoS One Date: 2012-05-07 Impact factor: 3.240
Authors: Symon M Kariuki; Evelyn Gitau; Samson Gwer; Henry K Karanja; Eddie Chengo; Michael Kazungu; Britta C Urban; Charles R J C Newton Journal: J Infect Dis Date: 2013-09-16 Impact factor: 5.226